Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review

J Am Acad Dermatol. 2024 Oct;91(4):753-755. doi: 10.1016/j.jaad.2024.06.037. Epub 2024 Jun 21.

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; New York Medical College, Valhalla, New York.
⁴ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
⁵ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Electronic address: [email protected].

No abstract available

Keywords: SJS; TEN; adnexal tumor; cutaneous effects; enfortumab vedotin; urothelial cancer.

Publication types